Detail of the clinical trial

Title of the trial A phase 3, multicenter, randomized, open-label, parallel-group study of the efficacy and safety of lenalidomide (Revlimid) versus chlorambucil as first-line therapy for previously untreated elderly patients with B-cell chronic lymphocytic leukemia (the origin trial)
EudraCT number 2008-003079-32
Protocol number CC-5013-CLL-008
Sponsor Celgene Corporation
Indications Oncology
Diagnosis B-cell chronic lymphocytic leukemia
Population in clinical trial Adults (18-65 years)
Elderly ( > 65 years)
Male
Female
Patients
Year of receiving the request to Institute (SÚKL) 2009
Date of approval by Institute (SÚKL) 14.9.2009; prodlouž.13.8.2010 +11.8.2011
Date of approval by EC 4.4.2013
Date of initiation CT in ČR 24.1.2012
Date of ending CT in ČR 20.7.2018 (23.4.2018)
Notice
Sites Fakultní nemocnice Hradec Králové, 2. Interní klinika - oddělení klinické hematologie, Sokolská 581, 500 05 Hradec Králové
FNKV, Oddělení klinické hematologie, Šrobárova 50, 100 34 Praha 10 (discontinued)
Ústav klinické hematologie, FN Ostrava (discontinued)

‹‹ Back to list